Annual Scientific Report

Spin-off companies
The knowledge dealt with from the IDIBAPS usually completes its cycle when transferred to the industry. In other cases the
link with the centre is maintained through the creation of spin-off companies.
A new company has been created in the course of 2010:
ImmunNovative Developments S.L. (IND). This spin-off company was created in February 2010, based on the transference
of two patents pertaining to the University of Barcelona, the Hospital Clínic de Barcelona, and the Fundació Clínic per
a la Recerca Biomèdica. The activity of IND focuses on the development of new biological therapies for the prevention and
treatment of inflammatory disorders with an immune basis.
For further information: www.immunnovative.com
Other spin-off companies in the setting of the IDIBAPS are:
Bionure (2009). Spin-off of Hospital Clínic/IDIBAPS and CSIC for the development of new neuroprotective drugs for the
treatment of multiple sclerosis and other neurological diseases.
For further information: www.bionure.com
Transmural Biotech (2009). Spin-off of the Hospital Clínic and the UB, for the development and commercialization of different
diagnostic devices in the gynecology field.
For further information: www.transmuralbiotech.com
Health Services (2009). Linkcare HS administers a Patient-Centric, Case Management oriented Open Health Care model
that has been designed as a joined effort of several leading medical care research centers in Europe leaded by Hospital
Clínic. Linkcare’s Open Source platform links clinical data from different systems such as Primary Care Information (PCIS),
Hospital Information (HIS), Electronic Health Record (EHR) and Enterprise Resource Programming (ERP) Systems with a
library of customized patient profile protocols. Linkcare application main areas are: Chronicity, Fragility, End of life care, Reproduction
and perinatology, Wellness and Clinical Research.
For further information: info@linkcare.es
Neurotec Pharma (2006). A R&D company which centres its activity on the development of new diagnostic and therapeutic
tools for acute and chronic central nervous system diseases that occur with inflammation and/or neurodegeneration such
as Stroke, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson (PD) and Alzheimer disease (AD), among
others.
For further information: www.neurotec-pharma.com
22